Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
4.010
+0.030 (0.75%)
At close: Dec 20, 2024, 4:00 PM
4.090
+0.080 (2.00%)
After-hours: Dec 20, 2024, 4:21 PM EST
Larimar Therapeutics Employees
Larimar Therapeutics had 42 employees as of December 31, 2023. The number of employees increased by 16 or 61.54% compared to the previous year.
Employees
42
Change (1Y)
16
Growth (1Y)
61.54%
Revenue / Employee
n/a
Profits / Employee
-$1,542,214
Market Cap
255.86M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 42 | 16 | 61.54% |
| Dec 31, 2022 | 26 | -5 | -16.13% |
| Dec 31, 2021 | 31 | 3 | 10.71% |
| Dec 31, 2020 | 28 | 12 | 75.00% |
| Dec 31, 2019 | 16 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TruBridge | 3,219 |
| Lifecore Biomedical | 524 |
| Lexicon Pharmaceuticals | 285 |
| Senseonics Holdings | 132 |
| Chimerix | 72 |
| Rezolute | 51 |
| Renovaro | 25 |
| Eledon Pharmaceuticals | 20 |
LRMR News
- 4 days ago - What's Going On With Larimar Therapeutics Stock On Tuesday? - Benzinga
- 5 days ago - Why Is Larimar Therapeutics Stock Trading Lower On Monday? - Benzinga
- 5 days ago - Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia - GlobeNewsWire
- 7 weeks ago - Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 2 months ago - Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga
- 2 months ago - Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha
- 3 months ago - Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research - GlobeNewsWire
- 7 months ago - Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed - Seeking Alpha